N
N05AG02 Pimozide
[N05AG] Diphenylbutylpiperidine derivatives
[N05A] ANTIPSYCHOTICS
[N05] PSYCHOLEPTICS
[N] Nervous system
Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
---|---|---|---|---|---|---|---|---|
ELECTRON TRANSPORT CHAIN | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | decrease | 53 | |||
ELONGATION | mouse | neuron | Mitochondrial morphology and neurite area measurements | induce | 269 | |||
Pictogram | Signal | Statements | Precautionary Statement Codes |
---|---|---|---|
Warning |
Aggregated GHS information provided by 45 companies from 5 notifications to the ECHA C&L Inventory. H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P264, P270, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
062P784 | 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone | 1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one |
1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one | 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine | 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone |
1-[1-[4,4-Bis(p-flurophenyl)butyl]-4-piperidyl]-2-benzimidazolinone | 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one | 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine |
1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(Pimozide) | 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one | 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one |
1-{1-[4,4-bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one | 117210-EP2272537A2 | 117210-EP2275420A1 |
117210-EP2295061A1 | 117210-EP2298776A1 | 1HIZ4DL86F |
2-Benzimidazolinone, 1-(1-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)- | 2-Benzimidazolinone, 1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]- | 2-Benzimidazolinone,4-bis(p-fluorophenyl)butyl]-4-piperidyl]- |
2062-78-4 | 2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- | 2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro- |
2H-Benzimidazol-2-one,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro- | 3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidyl]-1H-benzimidazol-2-one | 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one |
5-24-02-00367 (Beilstein Handbook Reference) | AB00052215 | AB00052215-06 |
AB00052215_07 | AB00052215_08 | AKOS024458706 |
AOB5780 | API0003851 | AS-13916 |
BCBcMAP01_000043 | BDBM50334150 | BG0381 |
BIDD:GT0435 | BPBio1_000304 | BRD-K01292756-001-06-0 |
BRD-K01292756-001-13-6 | BRN 0729089 | BSPBio_000276 |
BSPBio_001439 | BSPBio_002941 | C07566 |
C28H29F2N3O | CAS-2062-78-4 | CCG-35918 |
CCG-36461 | CCG-39728 | CCRIS 9172 |
CHEBI:8212 | CHEMBL1423 | CS-0012921 |
CTK8G2428 | D00560 | DB01100 |
DSSTox_CID_3474 | DSSTox_GSID_23474 | DSSTox_RID_77042 |
DTXSID8023474 | DivK1c_000386 | EINECS 218-171-7 |
EU-0100946 | FT-0673903 | GTPL90 |
HMS1568N18 | HMS1791H21 | HMS1921H19 |
HMS1989H21 | HMS2089C11 | HMS2092F09 |
HMS2095N18 | HMS2231P23 | HMS3262N14 |
HMS3267E19 | HMS3370N13 | HMS3402H21 |
HMS3411J16 | HMS3675J16 | HMS3712N18 |
HMS501D08 | HY-12987 | IDI1_000386 |
J-013477 | KBio1_000386 | KBio2_000925 |
KBio2_003493 | KBio2_006061 | KBio3_002441 |
KBioGR_000720 | KBioSS_000925 | KS-000018AL |
L000494 | LP00946 | LS-33236 |
Lopac-P-1793 | Lopac0_000946 | M828 |
MFCD00055081 | MLS000028410 | MLS001077311 |
MLS002702058 | McN-JR 6238 | McN-JR-6238 |
N-benzyl-N-(3-isobutoxy-2-(pyrrolidin-1-yl)propyl)benzenamine | NCGC00015802-01 | NCGC00015802-02 |
NCGC00015802-03 | NCGC00015802-04 | NCGC00015802-05 |
NCGC00015802-06 | NCGC00015802-07 | NCGC00015802-08 |
NCGC00015802-09 | NCGC00015802-10 | NCGC00015802-11 |
NCGC00015802-12 | NCGC00015802-13 | NCGC00015802-14 |
NCGC00015802-15 | NCGC00015802-16 | NCGC00015802-18 |
NCGC00015802-26 | NCGC00016601-01 | NCGC00022282-03 |
NCGC00024888-01 | NCGC00024888-02 | NCGC00024888-03 |
NCGC00024888-04 | NCGC00024888-05 | NCGC00024888-06 |
NCGC00024888-07 | NCGC00255294-01 | NCGC00261631-01 |
NCIMech_000356 | NINDS_000386 | NSC 170984 |
NSC-170984 | NSC-757854 | NSC170984 |
NSC757854 | Opera_ID_1580 | Opiran |
Orap | Orap (TN) | P 1793 |
PIMOZIDE1-{1-[4,4-BIS-(4-FLUORO-PHENYL)-BUTYL]-PIPERIDIN-4-YL}-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONE; | Pharmakon1600-01501134 | Pimozida [INN-Spanish] |
Pimozide (JP17/USP/INN) | Pimozide [USAN:INN:BAN:JAN] | Pimozide [USAN:USP:INN:BAN:JAN] |
Pimozide, European Pharmacopoeia (EP) Reference Standard | Pimozide, United States Pharmacopeia (USP) Reference Standard | Pimozidum |
Pimozidum [INN-Latin] | Prestwick0_000308 | Prestwick1_000308 |
Prestwick2_000308 | Prestwick3_000308 | Prestwick_395 |
Primozida | Primozida [INN-Spanish] | Primozide |
Q144085 | R 6238 | R-623 |
R-6238 | R6238 | SBI-0050920.P003 |
SCHEMBL41584 | SCHEMBL7519553 | SMP1_000241 |
SMR000058385 | SPBio_001211 | SPBio_002495 |
SPECTRUM1501134 | SR-01000075392 | SR-01000075392-1 |
SR-01000075392-3 | SR-01000075392-4 | SR-01000075392-6 |
SW196639-3 | Spectrum2_001026 | Spectrum3_001451 |
Spectrum4_000420 | Spectrum5_001308 | Spectrum_000445 |
Tocris-0937 | Tox21_110224 | Tox21_110224_1 |
Tox21_301586 | Tox21_500946 | UNII-1HIZ4DL86F |
WLN: T56 BMVNJ D- DT6NTJ A3YR DF&R DF | YVUQSNJEYSNKRX-UHFFFAOYSA-N | Z241910386 |
ZINC4175630 | pimozida | pimozide |